---
layout: default
title: Follitropin
parent: 僅模型預測 (L5)
nav_order: 446
evidence_level: L5
indication_count: 10
---

# Follitropin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the provided Evidence Pack, I'll note several important data characteristics before presenting the report: `drug.original_indications` is an empty array and `original_moa` is flagged `[Data Gap]` (matching data-gap DG002), and `taiwan_regulatory.licenses` is empty (drug not marketed in Singapore, DG001 also blocks safety review). Per the prohibition against fabricating data, I have not invented a formal "approved indication text" for Singapore — where a field cannot be populated from the Evidence Pack, I've stated that explicitly rather than guessing, while noting Follitropin's well-established pharmacological class (recombinant FSH used in ovulation induction/ART) only as background context, not as sourced regulatory data.

---

# Follitropin: From Infertility (Ovulation Induction) to Allergic Asthma

## One-Sentence Summary

Follitropin (recombinant follicle-stimulating hormone, FSH) is a gonadotropin used to induce ovulation and support controlled ovarian stimulation in infertility/assisted reproductive technology — no formal indication record is present in this Evidence Pack, and Singapore licensing data confirms the product is **not currently marketed** here. The TxGNN model's top prediction is **Allergic Asthma**, but this is currently supported only by **4 indirect literature references** (mechanism/observational studies) and **0 clinical trials**, making the evidence base weak.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in this Evidence Pack (`original_indications` empty, Singapore has no licenses on file). Generally known pharmacology: infertility / ovulation induction (ART) |
| Predicted New Indication | Allergic Asthma |
| TxGNN Prediction Score | 96.32% |
| Evidence Level | L4 (mechanism/preclinical-type literature only, no clinical trials) |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Follitropin in this Evidence Pack (data gap DG002). Based on generally known pharmacological information, Follitropin belongs to the gonadotropin class — it is a recombinant form of follicle-stimulating hormone (FSH) that binds FSH receptors to drive follicular development, and its efficacy in ovulation induction/controlled ovarian stimulation for infertility is well established in clinical practice.

The mechanistic rationale offered for allergic asthma is indirect. The supporting literature centers on **activin A**, a cytokine in the TGF-β superfamily that plays a role in asthmatic airway inflammation and remodeling — activin A is biologically related to FSH only in the sense that FSH-associated inhibin/activin research shares the same signaling superfamily, not through a direct pharmacological link to exogenous FSH itself. A second strand of evidence concerns associations between endogenous sex steroid hormones and allergic disease susceptibility (in children) and postmenopausal-onset bronchial asthma. None of these studies test Follitropin (or any exogenous FSH product) as a treatment for asthma; they describe correlative, endogenous-hormone biology rather than an interventional effect of the drug itself.

Given the absence of any clinical trial evidence and the indirect nature of the literature (activin A ≠ FSH; endogenous hormone correlation ≠ drug efficacy), the mechanistic plausibility for repurposing Follitropin in allergic asthma should be regarded as a hypothesis-generating signal only, not a validated pharmacological rationale.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [25962695](https://pubmed.ncbi.nlm.nih.gov/25962695/) | 2015 | Review | Clinical and Experimental Allergy | Reviews activin A (TGF-β superfamily, originally identified as an FSH-release inducer) as an immunoregulatory and fibrotic driver in asthmatic airway inflammation and remodeling |
| [31416681](https://pubmed.ncbi.nlm.nih.gov/31416681/) | 2019 | Review | Journal of Autoimmunity | Reviews activin-A's broad immune-regulatory roles in allergy, autoimmunity, and cancer; notes its initial identification as an FSH-secretion inducer |
| [37735641](https://pubmed.ncbi.nlm.nih.gov/37735641/) | 2023 | Cohort | BMC Pediatrics | Pilot birth-cohort study examining associations between sex steroid hormones and allergic disease in Japanese children |
| [3081834](https://pubmed.ncbi.nlm.nih.gov/3081834/) | 1986 | Case series/Observational | Minerva Medica | Observational study of hypophyseal/gonadal hormone (including FSH) profiles in women with postmenopausal-onset bronchial asthma vs. allergic asthma controls |

---

## Safety Considerations

Please refer to the package insert for safety information. (This Evidence Pack's key warnings, contraindications, and drug-interaction fields are all marked as data gaps, and DDI lookup returned no results. Note: data gap DG001 — TFDA/HSA label warnings/contraindications — is flagged **Blocking**, meaning a formal safety (S1) evaluation cannot proceed until this is resolved.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The allergic asthma prediction is supported only by indirect, mechanism-level literature (activin A biology and endogenous hormone associations) with zero clinical trials directly testing Follitropin in asthma, placing it at evidence level L4. Combined with the blocking safety data gap (no TFDA/HSA label data) and the drug's non-marketed status in Singapore, there is insufficient evidence to proceed beyond a research-question stage.

**To proceed, the following is needed:**
- Resolve blocking data gap DG001: obtain official label warnings/contraindications before any S1 safety evaluation
- Resolve data gap DG002: obtain confirmed mechanism of action (MOA) data from DrugBank
- Confirm actual original/approved indication(s) for Follitropin, since `original_indications` is currently empty in this pack
- Seek direct pharmacological or clinical evidence (in vitro/in vivo or trial data) linking exogenous FSH administration to asthma outcomes, rather than relying on activin A/endogenous-hormone correlation studies
- Reassess market/regulatory pathway, given the drug is not currently registered in Singapore
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

